The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus

Haematologica

Volumn 91, Issue 5, 2006, Pages 699-702

  Nojima, Junzo ^a   Iwatani, Yoshinori ^b   Suehisa, Etsuji ^a   Kuratsune, Hirohiko ^c   Kanakura, Yuzuru ^b  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANSAI UNIVERSITY OF WELFARE SCIENCES   (Japan)

Author keywords

Anti 2 glycoprotein I antibodies; Anti phosphatidylserine prothrombin antibodies; Anti phospholipid antibodies; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ABORTION, HABITUAL; ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ARTERIAL OCCLUSIVE DISEASES; AUTOANTIBODIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; PREGNANCY; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33744493101     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999;93:2149-57
2. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67.
3. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-53.
4. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341-4.
5. Khamashta MA, Hughes GR. Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 1995;7:389-94.
6. Koike T, Matsuura E. Anti-β 2-glycoprotein I antibody: specificity and clinical significance. Lupus 1996;5:378-80.
7. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-906.
8. Cucurull E, Espinoza LR, Mendez E, Molina JF, Molina J, Ordi-Ros J, Gharavi AE. Anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus 1999;8:134-41.
9. Nojima J, Suehisa E, Akita N, Toku M, Fushimi R, Tada H, et al. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997;96:447-50.
10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
11. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24.
12. Triplett DA. Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters. Lupus 1996;5:431-5.
13. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
14. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to β(2)- glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001;47:1008-15.
15. Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against β2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005;51:545-52.
16. Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies: co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004;91:967-76.
17. Koike T, Ichikawa K, Kasahara H, Atsumi T, Tsutsumi A, Matsuura E. Epitopes on β2-GPI recognized by anticardiolipin antibodies. Lupus 1998;7 Suppl 2:514-7.
18. Nojima J, Suehisa E, Kuratsune H, Machii T, Koike T, Kitani T, et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus - possible association with thrombotic and thrombocytopenic complications. Thromb Haemost 1999;81:436-41.